Radiomics Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Preoperative Differentiation of Combined Hepatocellular-Cholangiocarcinoma from Hepatocellular Carcinoma: A Multi-Center Study

References

• Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol. 2021;74:1212–1224. doi:10.1016/j.jhep.2021.01.035
   PubMedGoogle Scholar
• Rosenberg N, Van Haele M, Lanton T, et al. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. J Hepatol. 2022;77:1631–1641. doi:10.1016/j.jhep.2022.07.029
   PubMed Web of Science ®Google Scholar
• Wang G, Wang Q, Liang N, et al. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell Death Dis. 2020;11:313 doi:10.1038/s41419-020-2509-x.
   PubMed Web of Science ®Google Scholar
• Moeini A, Sia D, Zhang Z, et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol. 2017;66:952–961. doi:10.1016/j.jhep.2017.01.010
   PubMedGoogle Scholar
• Park YH, Hwang S, Ahn CS, et al. Long-term outcome of liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma. Transplant Proc. 2013;45:3038–3040. doi:10.1016/j.transproceed.2013.08.056
   PubMed Web of Science ®Google Scholar
• Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Clin Pathol. 1949;4:647–655.
   Google Scholar
• Groeschl RT, Turaga KK, Gamblin TC. Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma. J Surg Oncol. 2013;107:608–612. doi:10.1002/jso.23289
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transplant. 2011;17:934–942. doi:10.1002/lt.22307
   PubMed Web of Science ®Google Scholar
• Kim KH, Lee SG, Park EH, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16:623–629. doi:10.1245/s10434-008-0278-3
   PubMed Web of Science ®Google Scholar
• Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120–125. doi:10.1016/j.amjsurg.2004.03.018
   PubMed Web of Science ®Google Scholar
• Liu C, Fan S, Lo C, et al. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg. 2003;138:86–90. doi:10.1001/archsurg.138.1.86
   PubMedGoogle Scholar
• Kim JH, Yoon HK, Ko GY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. RADIOLOGY. 2010;255:270–277. doi:10.1148/radiol.09091076
   PubMed Web of Science ®Google Scholar
• Lee W, Lee K, Heo J, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006;36:892–897. doi:10.1007/s00595-006-3276-8
   PubMed Web of Science ®Google Scholar
• Vilchez V, Shah MB, Daily MF, et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB. 2016;18:29–34. doi:10.1016/j.hpb.2015.10.001
   PubMed Web of Science ®Google Scholar
• Dahiya D, Wu T, Lee C, Chan K, Lee W, Chen M. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. SURGERY. 2010;147:676–685. doi:10.1016/j.surg.2009.10.043
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang Q, Li S, Luo R, Mao S, Shen J. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population. Clin Radiol. 2019;74:401–407. doi:10.1016/j.crad.2019.01.016
   Web of Science ®Google Scholar
• Li R, Yang D, Tang C, et al. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC CANCER. 2016;16:158. doi:10.1186/s12885-016-2156-x
   PubMed Web of Science ®Google Scholar
• Joo I, Lee JM, Lee DH, Jeon JH, Han JK. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol. 2019;29:1724–1732. doi:10.1007/s00330-018-5727-1
   PubMed Web of Science ®Google Scholar
• Fraum TJ, Tsai R, Rohe E, et al. Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the liver imaging reporting and data system version 2014. RADIOLOGY. 2018;286:158–172. doi:10.1148/radiol.2017170114
   PubMed Web of Science ®Google Scholar
• Zhou C, Lu X, Wang Y, Qian X, Yang C, Zeng M. Histopathological components correlated with MRI features and prognosis in combined hepatocellular carcinoma-cholangiocarcinoma. Eur Radiol. 2022;32:6702–6711. doi:10.1007/s00330-022-09065-y
   PubMed Web of Science ®Google Scholar
• Kim T, Kim H, Joo I, Lee JM. Combined hepatocellular-cholangiocarcinoma: changes in the 2019 world health organization histological classification system and potential impact on imaging-based diagnosis. Korean J Radiol. 2020;21:1115. doi:10.3348/kjr.2020.0091
   PubMed Web of Science ®Google Scholar
• Li C, Zheng X, Guo H, et al. Differentiation between combined hepatocellular cholangiocarcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasonics-based model and CEUS LI-RADS v2017. BMC Med Imaging. 2022;22:36. doi:10.1186/s12880-022-00765-x
   PubMed Web of Science ®Google Scholar
• Lu L, Zhang C, Yu X, et al. The value of contrast-enhanced magnetic resonance imaging enhancement in the differential diagnosis of hepatocellular carcinoma and combined hepatocellular cholangiocarcinoma. J Oncol. 2022;2022:4691172 doi:10.1155/2022/4691172.
   PubMed Web of Science ®Google Scholar
• Zwanenburg A, Vallières M, Abdalah MA, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. RADIOLOGY. 2020;295:328–338. doi:10.1148/radiol.2020191145
   PubMed Web of Science ®Google Scholar
• Hwang J, Kim YK, Park MJ, et al. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2012;36:881–889. doi:10.1002/jmri.23728
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou G, Zhang J, Xu C, Zhu F, Xu P. DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma. Eur Radiol. 2022;7:5004–5015. doi:10.1007/s00330-022-08548-2
   Google Scholar
• Yin P, Mao N, Zhao C, et al. Comparison of radiomics machine-learning classifiers and feature selection for differentiation of sacral chordoma and sacral giant cell tumour based on 3D computed tomography features. Eur Radiol. 2019;29:1841–1847. doi:10.1007/s00330-018-5730-6
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu H, Zeng J, et al. Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study. World J Surg Oncol. 2022;20:20. doi:10.1186/s12957-022-02488-3
   PubMed Web of Science ®Google Scholar
• Park HJ, Park B, Park SY, et al. Preoperative prediction of postsurgical outcomes in mass-forming intrahepatic cholangiocarcinoma based on clinical, radiologic, and radiomics features. Eur Radiol. 2021;31:8638–8648. doi:10.1007/s00330-021-07926-6
   PubMed Web of Science ®Google Scholar
• Shan Q, Hu H, Feng S, et al. CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. CANCER IMAGING. 2019;19:19. doi:10.1186/s40644-019-0203-y
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang X, Zhang L, et al. Radiomics predict postoperative survival of patients with primary liver cancer with different pathological types. Ann Transl Med. 2020;8:820. doi:10.21037/atm-19-4668
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jiang H, Chen J, et al. Hepatocellular carcinoma: radiomics nomogram on gadoxetic acid-enhanced MR imaging for early postoperative recurrence prediction. CANCER IMAGING. 2019;19:22 doi:10.1186/s40644-019-0209-5.
   PubMed Web of Science ®Google Scholar
• Li YM, Zhu YM, Gao LM, et al. Radiomic analysis based on multi-phase magnetic resonance imaging to predict preoperatively microvascular invasion in hepatocellular carcinoma. World J Gastroenterol. 2022;28:2733–2747. doi:10.3748/wjg.v28.i24.2733
   PubMed Web of Science ®Google Scholar
• Gao L, Xiong M, Chen X, et al. Multi-region radiomic analysis based on multi-sequence MRI can preoperatively predict microvascular invasion in hepatocellular carcinoma. Front Oncol. 2022;12:818681 doi:10.3389/fonc.2022.818681.
   PubMed Web of Science ®Google Scholar
• Lv K, Cao X, Du P, Fu JY, Geng DY, Zhang J. Radiomics for the detection of microvascular invasion in hepatocellular carcinoma. World J Gastroenterol. 2022;28:2176–2183. doi:10.3748/wjg.v28.i20.2176
   PubMed Web of Science ®Google Scholar
• Choi SH, Lee SS, Park SH, et al. LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI. RADIOLOGY. 2019;290:388–397. doi:10.1148/radiol.2018181290
   PubMed Web of Science ®Google Scholar
• Song D, Zhu K, Tan J, et al. Perioperative and oncologic outcomes of laparoscopic versus open liver resection for combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis. Surg Endo. 2022;37(2):967–976 doi:10.1007/s00464-022-09579-y.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zheng X, Zhou C, et al. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction. Eur Radiol. 2022;33:1412–1421. doi:10.1007/s00330-022-09131-5
   PubMed Web of Science ®Google Scholar
• Jeon SK, Joo I, Lee DH, et al. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol. 2019;29:373–382. doi:10.1007/s00330-018-5605-x
   PubMed Web of Science ®Google Scholar